The FDA has approved AstraZeneca's breast cancer treatment Arimidex (anastrozole) as a new treatment option for postmenopausal women first diagnosed with advanced or locally advanced breast cancer whose cancers are hormone receptive.
Arimidex is the first aromatase inhibitor to be approved for first-line treatment in the United States. Arimidex previously was only approved for use after disease progression following tamoxifen treatment. AstraZeneca reported that two pivotal studies found that Arimidex was as effective and well tolerated as tamoxifen when prescribed at the time of diagnosis for women with advanced breast cancer.
COPYRIGHT 2000 Lebhar-Friedman, Inc.
COPYRIGHT 2000 Gale Group